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In the Western world, endometrial cancer (EC) is the most common malignant tumor of the female genital tract. Solid tumors like
EC outgrow their vasculature resulting in hypoxia. Tumor hypoxia is important because it renders an aggressive phenotype and
leads to radio- and chemo-therapy resistance. Hypoxia-inducible factor-1α (HIF-1α) plays an essential role in the adaptive cellular
response to hypoxia and is associated with poor clinical outcome in EC. Therefore, HIF-1 could be an attractive therapeutic
target. Selective HIF-1 inhibitors have not been identiﬁed. A number of nonselective inhibitors which target signaling pathways
upstreamordownstreamHIF-1areknowntodecreaseHIF-1αproteinlevels.Inclinicaltrialsforthetreatmentofadvancedand/or
recurrent EC are the topoisomerase I inhibitor Topotecan, mTOR-inhibitor Rapamycin, and angiogenesis inhibitor Bevacizumab.
Preliminary data shows encouraging results for these agents. Further work is needed to identify selective HIF-1 inhibitors and to
translate these into clinical trials.
1.Introduction
Endometrial cancer is the most common malignant tumour
of the female genital tract. The American Cancer Society
estimates that 42.160 women will have been diagnosed with,
and 7780 women will have died of cancer of endometrial
cancer in 2009 in the US [1]. Ninety percent of endometrial
cancer cases are sporadic, while the remaining are deemed
hereditary. In the endometrium, diﬀerent adenocarcinoma
subtypes can develop. Endometrioid endometrial carcinoma
(EEC), or Type 1 cancer, accounts for approximately 75%
of cases. These tumours are usually oestrogen dependent,
tend to be of lower grade, and have fewer recurrences and
a better survival. They often develop in a background of
adenomatous hyperplasia and are characterized by muta-
tions in PTEN and defects in DNA mismatch repair—as
manifested by microsatellite instability. Type 2 tumours, of
which serous endometrial carcinoma (USPC) is the most
common subtype, arise from atrophic endometrium. Type 2
tumours often show p53 and are usually nondiploid. USPCs
are often poorly diﬀerentiated and have a greater propensity
for early spreading. They have worse prognosis than that of
EEC.
A developing solid tumour will outgrow its own vascu-
lature beyond the size of several cubic millimetres, result-
ing in hypoxia (deﬁned as an oxygen tension below the
physiological level, <2% pO2)[ 2]. Hypoxia has been found
to be an important event in carcinogenesis as it renders a
more aggressive phenotype with increased invasiveness and
proliferation, formation of metastases, and poorer survival
in several types of cancer [3, 4]. Furthermore, it has been
shown that hypoxia-induces resistance to radiotherapy and
chemotherapy [5–7]. The key survival gene for cells in a
hypoxic environment is hypoxia inducible factor-1 (HIF-1)
(see Figure 1.).
The unsatisfactory results obtained with conventional
pharmacological treatment encourage further biological and
clinical investigations addressed to a better understanding
of speciﬁc cell targets and signalling transduction pathways
involved in endometrial carcinogenesis and to the identiﬁ-
cation of novel molecular therapeutic targets. As hypoxia,
and thus HIF-1, leads to resistance to radiotherapy and2 Obstetrics and Gynecology International
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Figure 1: Mechanisms of HIF activation in cancer.
chemotherapy in solid tumours [5–8], targeting HIF-1 could
be an attractive treatment strategy, with the potential for
disrupting multiple pathways crucial for tumour growth.
In this review, we will describe the current status of HIF-1
(upstream and downstream) inhibitors in the treatment of
endometrial cancer.
2. Hypoxia-InducibleFactor-1α
HIF-1 is a transcription factor composed of the subunits
HIF-1α and HIF-1β, which are basic helix-loop-helix DNA
binding proteins. Both HIF-1α and HIF-1β genes are ubiq-
uitously expressed and heterodimerize to form the active
HIF-1 that activates gene transcription by binding to the
consensus HIF Responsive Element (HRE): 5 -RCGTG-
3  in promoters and enhancers of target genes [9]. The
activity of HIF-1 is predominantly regulated at the post-
translational level by regulating HIF- 1α protein stability. At
normal oxygen tension, HIF-1α is hydroxylated by prolyl
hydroxylases (PHD) in the oxygen dependent degradation
domain (ODDD). Hydroxylated HIF-1α is recognized by
the Von Hippel-Lindau (VHL) protein, ubiquitinated and
destined for degradation by proteasomes. This process
is inhibited during hypoxia [10]. Under hypoxia, stabi-
lized HIF-1α subunits heterodimerize with β subunits (also
known as ARNT) to transactivate target genes after nuclear
translocation. Among these are genes involved in adaptation
to low glucose levels like the glucose transporter Glut-
1, carboanhydrase IX (CAIX) that regulates pH [11], and
vascular endothelial growth factor (VEGF) that is one of
the most potent inducers of angiogenesis [12]. Although
HIF-1α usually induces prosurvival (CAIX, Glut-1, VEGF)
g e n e s ,ar o l eo fH I F - 1 α in regulation of apoptosis has also
been described. HIF-1α promotes cell death through an
increase in p53 or other proapoptotic proteins like BNIP3
[13]. As a result of this dual function of HIF-1α,a“ s t o p -
and-go” strategy as a dynamic balance to maintain overall
cell growth and survival has been proposed [14]. Hypoxia
induced HIF-1α also aﬀects the expression of genes involved
in metastasis formation. Hepatocyte growth factor (HGF),
for example, is a cytokine which stimulates proliferation
and invasion through its receptor, the protooncogene c-MET
[15]. Invasive cell growth is promoted by HIF-1α -induced c-
Met transcription and sensitizing of cells to HGF stimulation
[16–18]. Taken together, the adaptive response to hypoxiaObstetrics and Gynecology International 3
in primary tumours resembles in many ways the so-called
metastatic phenotype which explains the poor prognosis of
hypoxic cancers [19].
HIF-1 stabilization may also occur under oxygen-
independent conditions, including infection with oncogenic
viruses, loss-of-function mutations in tumour suppressor
genes such as Von Hippel-Lindau (VHL), or signaling
by receptor tyrosine kinases, prostaglandin E2 receptor,
or nitric oxide [20]. Furthermore, genetic alterations in
the EGFR [21], RAS, and PI-3K/Akt [22–24]a sw e l la s
loss of p53 function [25] have been shown to lead to
increased nonhypoxic HIF activity. HIF-1α has also been
shown to be regulated by mammalian target of Rapamycin
(mTOR). mTOR promotes increased translation of HIF-1α
mRNA into protein [26, 27]. Other possible mechanisms
contributing to normoxic HIF-1 expression like oncogenic
mutation or ampliﬁcation of HIF-1α gene have rarely been
reported in solid cancers [28, 29]. A polymorphism in
HIF-1α (P582S) has been found associated with increased
HIF activity and poor prognosis in prostate cancer, but
its signiﬁcance with cancer risk is still incompletely under-
stood [30, 31]. The single nucleotide polymorphism (SNP)
C1772T (also described as C1744T) in the HIF-1α gene
coding region results in an amino acid change at position
582 changing a Proline to a Serine (i.e., P582>S) in the
ODD domain (http://www.ncbi.nlm.nih.gov/SNP/snp ref.
cgi?rs=11549465). Carriers of this SNP seemed to have an
increased risk of developing cervical and endometrial cancer
[32]. However, the proportion of allele carriers with the
most common polymorphism in the control group was
diﬀerent from ratios described in other studies. We [31]
examined whether the C1744T polymorphism increased
the risk for endometrioid endometrial cancer. Although
the C1744T polymorphism was associated with higher
microvessel density and AKT activation, it did not lead to
increased cancer risk. Interestingly we found that the P582S
genotype variation in the ODDD of the HIF-1α protein may
occurasadenovomutationinendometrialcancer.Although
the signiﬁcance of this remains to be established, others have
proposedthatitmayincreasetransactivationofHIF-1α[30].
3.EndometrialCancer
3.1. HIF-1α and Endometrial Carcinogenesis. It has been
postulated that menstruation results from vasoconstriction
of spiral arterioles, causing hypoxia which leads to necrosis
[33]. This focal hypoxia in perimenstrual endometrium
could result in locally increased HIF-1α.H o w e v e r ,i np r e -
menopausal women, HIF-1α was undetectable in the major-
ity of samples. In the HIF-1α positive cases, expression was
only seen in a small focus within the tissue, suggesting that
if hypoxia does occur at this time, then it is not widespread.
There seemed to be no correlation of HIF-1α expression and
themenstrualcycle[34].Inpostmenopausalwomen,HIF-1α
was increasingly overexpressed from inactive endometrium
through hyperplasia to endometrioid carcinoma, paralleled
by activation of its downstream genes such as CAIX, Glut-1,
VEGF, and increased angiogenesis. Low HIF-1α expression
was associated with negative/low VEGF staining in the total
group [35]. These results highlight the potential importance
of hypoxia and its key regulator HIF-1α in endometrial
carcinogenesis and progression of disease [36].
Perinecrotic, chronic hypoxia-associated HIF-1α expres-
sion was absent in inactive endometrium, rare in endome-
trial hyperplasia, and frequent in endometrioid carcinoma.
These results could point to the importance of hypoxia
and the subsequent stabilization of HIF-1α in endometrial
carcinogenesis [35–38]. Loss of PTEN tumour suppressor
gene (also known as MMAC1) is often seen in endometrial
carcinogenesisandisthoughttocausenonhypoxia-mediated
HIF-1α expression via activation of the PI3K/AKT and
mTOR signaling pathway [39–42]. Horr´ ee et al. (unpub-
lished data) showed that although over 60% of the car-
cinomas showed extensive loss of PTEN by immunohis-
tochemistry, this was not correlated to increased HIF-1α
expression. Thus, diﬀuse nonhypoxia-related expression of
HIF-1α seemed not to be related to PTEN mutation in
endometrial cancer. Correlation of HIF-1α with tumour
s t a g e ,t u m o u rg r a d e ,o rm y o m e t r i a li n v a s i o ni ss t i l lu n d e r
discussion [35, 43, 44].
The mechanism of tumourigenesis of USPC diﬀers from
that of EEC. More expression of HIF-1α was observed in
USPC than in EEC [44, 45]. In USPC, HIF-1α expression
was not correlated to clinical stage or depth of myometrial
invasion. p53 mutations are a common event in USPC
carcinogenesis and aberrant p53 accumulation has been
associated with HIF-1α overexpression in diﬀerent human
tumours [46]. In contrast, p53 expression was not associated
with HIF-1α expression in type II endometrial carcinomas
[44, 45].
3.2. HIF-1α and Prognosis in Endometrial Cancer. Contra-
dictory results have been described as to the prognostic
value of HIF-1α overexpression in endometrial carcinoma.
HIF-1α showed signiﬁcantly higher expression in recur-
rent endometrial carcinomas when compared with their
primary tumours; it was, however, not an independent
predictor for recurrent endometrial carcinoma [43, 44].
In stage 1 endometrial cancers, HIF-1α was associated
with a worse prognosis [37]. However, others did not
ﬁ n dp r o g n o s t i ci m p a c to fH I F - 1 α expression [38]. Besides
the limitation of relatively small numbers of patients in
these studies, immunohistochemical studies are diﬃcult to
compare because of a variation in deﬁnition of HIF-1α
positivity. In some studies, both nuclear and cytoplasmic
staining was scored. The signiﬁcance of cytoplasmic HIF-
1α, however, is still not clear as stable HIF-1α is thought to
rapidly translocate to the nucleus. Expression patterns that
can be observed in endometrial tumours are the diﬀuse,
perinecrotic, and mixed (both perinecrotic and diﬀuse)
patterns [35]. Perinecrotic HIF-1α expression is thought to
be hypoxia driven, whereas diﬀuse HIF-1α expression may
rather be due to nonhypoxic stimuli [47]. Our experience
shows that once authors take into account nuclear staining
only and HIF-1α expression pattern, the results can change
dramatically. Figure 2 shows an example of nuclear HIF-1α
in a diﬀuse and perinecrotic expression pattern.4 Obstetrics and Gynecology International
Table 1: Clinical trials on HIF-1α targeted therapies in endometrial cancer.
Class Inhibitor Mechanism
Clinical trials in
endometrial
cancer
Small molecule inhibitors of HIF-1
Topoisomerase inhibitor Topotecan (topo-I)
Inhibits hypoxic
induction of HIF-1α
protein and DNA
binding activity
Miller et al. [48]
Triana et al. [49]
Wadler et al.
[50]
HSP90 inhibitor Geldanamycin
Induces degradation of
HIF-1α protein and
inhibition of DNA
binding of HIF-1
—
Other PX-478 Inhibition of HIF-1α
transcription activity —
Inhibitors of signal transduction pathways
mTOR inhibitor Temsirolimus (CCI-779)
Downregulation of
HIF-1α by inhibing
mTor
Oza et al. [51]
Everolimus (RAD001) Slomovitz et al.
[52]
Inhibitors of HIF-1 target genes
VEGF inhibitor Bevacizumab Monoclonal antibody
against VEGF
Aghajanian et al.
[53]
CAIX inhibitor Rencarex (WX G250) Monoclonal antibody
against CAIX —
As HIF-1α expression is associated with treatment failure
and/or patient mortality, targeting HIF-1α could be an
attractive treatment strategy, with the potential for disrupt-
ing multiple pathways crucial for tumour growth.
4.HIF-1αandHypoxiaas
a Target for Cancer Therapy
The unsatisfactory results obtained with conventional phar-
macological treatment encourage further biological and
clinical investigations addressed to a better understanding
of speciﬁc cell targets and signaling transduction pathways
involved in endometrial carcinogenesis and to the identiﬁca-
tion of novel molecular targeted therapies. A new and more
eﬀective treatment for metastatic endometrial carcinoma is
urgently needed.
There are diﬀerent areas of research in hypoxia-related
drug therapy including (1) designing drugs that directly
inhibit HIF-1 signaling and (2) inﬂuencing other signaling
cascades that indirectly alter HIF signaling.
Inhibition of HIF-1α would, of course, hit multiple
targets but because of its bifunctional eﬀects, for example,
proapoptotic genes induced by hypoxia, outcome will be
diﬃcult to predict. Thus far, selective HIF-1 inhibitors have
not been identiﬁed. A number of nonselective inhibitors,
which indirectly target signaling pathways upstream or
downstream HIF-1 are known to decrease HIF-1α protein
levels. Antisense therapy against HIF-1α has been shown
to reduce HIF-1α expression and transcriptional activity;
however, at present it is not clinically applicable. Therefore,
the potential of HIF-1α as a target for cancer therapy lies
in the small molecule inhibitors of HIF-1. Several small
molecular inhibitors of the HIF-1 transcriptional activation
pathway have been identiﬁed (Table 1). Although none of
these has been shown to directly and speciﬁcally target HIF-
1[ 54, 55], they do decrease HIF-1α protein levels. Some
of these HIF-1 inhibitors are subject of clinical trials at
present.
4.1. Topotecan. Topotecan, a topoisomerase I inhibitor that
has been used as a second-line therapy for ovarian cancer,
is one such small molecule inhibitor of HIF-1 [56, 57].
Topotecan inhibits hypoxic induction of HIF-1α protein
and DNA binding activity [58]. In a GOG phase II trial of
Topotecan in pretreated patients with advanced, persistent,
or recurrent endometrial carcinoma, the total response rate
was 9%, with 1 patient achieving a complete response and
1 experiencing a partial response. Twelve (55%) patients
maintained stable disease [48]. The eastern Cooperative
Oncology Group subsequently performed a phase II trial
of Topotecan for metastatic or recurrent endometrial car-
cinoma. The overall response was 20%. Although single-
agentTopotecantreatmenthasshownactivityinchemona¨ ıve
[50] and previously treated patients [48, 49], severe (grade
4 neutropenia) and unexpected (primarily sepsis) toxicities
were encountered [48, 50]. However, at modiﬁed doses,Obstetrics and Gynecology International 5
(a)
(b)
Figure 2: Immunohistochemical staining of HIF-1α in endometri-
oid endometrial carcinoma. Typical patterns are shown: (a) per-
inecrotic HIF-1α expression (10× magniﬁcation) and (b) diﬀuse
HIF-1α expression (10× magniﬁcation).
toxicity was acceptable and clinical activity was preserved
[50].
Despite the diﬀerent carcinogenesis of EEC and USPC,
but probably due to the rareness of the latter, clinical
trials including only USPC patients are rare. A pilot study
of Topotecan for the treatment of USPC demonstrated
clinical activity in this patient group [59]. However, because
survival outcomes continue to be disappointing, combining
Topotecan with other active drugs may lead to improved
outcomes.
4.2. mTOR Inhibitors. HIF-1α has also been shown to be
regulated by mammalian target of Rapamycin (mTOR).
mTOR promotes increased translation of HIF-1α mRNA
into protein [26, 27]. Rapamycin is a speciﬁc inhibitor of
mTOR and inhibits both the stabilization and the tran-
scriptional activity of HIF-1α in hypoxic cancer cells [60].
This eﬀect is directly related to the disruption of mTOR-
dependentsignalingfunctions.Thecurrenthypothesisisthat
mTOR inhibitors could be eﬀective inhibitors of hypoxic
adaptation in developing tumours. These eﬀects could be
especially relevant in tumours with loss of PTEN function
as is often the case in endometrioid endometrial cancer
[61]. Loss of PTEN leads to constitutive activation of
AKT, which leads to up-regulation of mTOR. Potential
therapies targeting the mTOR pathway include mTOR
inhibitors (Rapamycin derivates) Temsirolimus (CCI-779),
and Everolimus (RAD001) [62]. Demonstrated activity in
preclinical studies has led to numerous phase I and phase
II trials. A phase II trial of Temsirolimus in patients with
chemotherapy treated, recurrent, or metastatic endometrial
cancershowedmodestactivityofTemsirolimus.Twopatients
(7.4%) showed partial response and twelve patients (44%)
had stable disease [51]. A 44% clinical beneﬁt response rate
was found in a phase II study of Everolimus in 29 patients
with recurrent endometrial cancer [52]. Clinical Beneﬁt
was deﬁned as complete or partial response or prolonged
stable disease. In this trial, loss of PTEN expression was
predicative of response rate. The diﬀerent mTOR inhibitors
show encouraging single agent clinical beneﬁt. A phase I trial
of Temsirolimus with Topotecan (NCT00523432) in patients
with gynaecological malignancies, including endometrial
cancer, has just ﬁnished recruiting patients. Other trials of
Temsirolimus are underway.
4.3. Bevacizumab. An HIF-1 inhibitor that targets a pathway
activated by HIF-1 is Bevacizumab. Bevacizumab is a mon-
oclonal antibody that targets VEGF, a potent endothelial cell
mitogenthathasbeenassociatedwithincreasedangiogenesis
in malignancies. Diﬀerent studies showed that an increase
in VEGF expression was linked to increased angiogenesis
in endometrial carcinomas. High VEGF mRNA levels were
correlated signiﬁcantly with highly vascularized tumours
[63, 64]. Early results of a phase II study of Bevacizumab in
the treatment of recurrent or persistent endometrial cancer
in 53 patients showed a 15% response rate. Nearly 36%
of the patients were progression free at 6 months [53]. In
conclusion,Bevacizumabappearstobeactiveinwomenwith
recurrent or persistent endometrial cancer.
4.4. Cisplatin and Doxorubicin. Some conventional anti-
cancer agents targeting signal transduction pathways have
also been shown to inhibit HIF-1 [65]. Duyndam et al.
[66] showed in human ovarian cancer cell lines that the
conventional anticancer agents cisplatin and doxorubicin
can negatively inﬂuence HIF-1 activity with a concomitant
reduction of VEGF expression. A recent phase III trial
demonstrated improved progression-free and overall sur-
vival for the three-drug regimen of cisplatin, doxorubicin
and paclitaxel compared with a two-drug combination (cis-
platin and doxorubicin) in advanced or recurrent endome-
trial carcinoma. However, toxicity problems often make the
three-drug regimen less acceptable [67].
4.5. New Promising Drugs. Small molecule inhibitors of
HIF-1 activity currently investigated in clinical trials are
PX-478, an inhibitor of HIF-1 transcription factor activity
[68], and geldanamycin, an HSP90 (heat shock protein 90)
inhibitor [69]. HSP90 is involved in the folding of HIF-1α
andGeldanamycininducesdegradationofHIF-1α[70].Both
are being evaluated in advanced solid tumours. WX G250,6 Obstetrics and Gynecology International
a CAIX antibody (http://www.wilex.com), is another HIF-1
inhibitor that targets a diﬀerent pathway activated by HIF-
1. WX G250 is currently in phase III clinical trials in renal
cell cancers. These new drugs may ﬁnd their way into clinical
trials in endometrial cancer in the future.
5. Summary
Hypoxic tumours are usually resistant to radiotherapy and
conventional chemotherapy, rendering them highly aggres-
sive and metastatic. Response to hypoxic stress is largely
mediated by the HIF pathway. HIF-1α expression is corre-
latedwithapoorprognosisinendometrialcancer.Therefore,
targeting the HIF pathway provides an attractive strategy
to treat hypoxic and highly angiogenic tumours. Thus far,
selectiveHIF-1inhibitorshavenotbeenidentiﬁed.Anumber
of nonselective inhibitors, which indirectly target signaling
pathways upstream or downstream of HIF-1, are known to
decrease the key regulating HIF-1α protein levels. Diﬀerent
(indirect) HIF-1α inhibitors that are in clinical trial for
the treatment of advanced/recurrent endometrial carcinoma
are Topotecan, Rapamycin derivates, and Bevacizumab.
Preliminaryresultsshowencouragingresultsforthesesingle-
agent treatments with partial response and stable disease
in the patients. However, lack of speciﬁcity increases the
diﬃculty in attributing any antitumorigenic eﬀects of these
drugs speciﬁcally to inhibition of HIF-1. The combination
of HIF inhibitors with conventional treatment may prove to
be clinically useful. Further work is needed to identify more
selective HIF-1 inhibitors, to determine their mechanism
of action, and to translate these developments into clinical
trials.
References
[ 1 ]A .J e m a l ,R .S i e g e l ,E .W a r d ,Y .H a o ,J .X u ,a n dM .J .T h u n ,
“Cancer statistics, 2009,” CA: A Cancer Journal for Clinicians,
vol. 59, pp. 225–249, 2009.
[2] I. J. Fidler and L. M. Ellis, “The implications of angiogenesis
for the biology and therapy of cancer metastasis,” Cell, vol. 79,
no. 2, pp. 185–188, 1994.
[3] T. Kurokawa, M. Miyamoto, K. Kato, et al., “Overexpression
of hypoxia-inducible-factor 1α(HIF-1α) in oesophageal squa-
mous cell carcinoma correlates with lymph node metastasis
and pathologic stage,” British Journal of Cancer, vol. 89, no. 6,
pp. 1042–1047, 2003.
[4] Q. T. Le, N. C. Denko, and A. J. Giaccia, “Hypoxic gene
expressionandmetastasis,”CancerandMetastasisReviews,vol.
23, no. 3-4, pp. 293–310, 2004.
[5] M. H¨ ockel, K. Schlenger, S. H¨ ockel, and P. Vaupel, “Hypoxic
cervical cancers with low apoptotic index are highly aggres-
sive,” Cancer Research, vol. 59, no. 18, pp. 4525–4528, 1999.
[6] P. Vaupel, O. Thews, and M. Hoeckel, “Treatment resistance of
solid tumors: role of hypoxia and anemia,” Medical Oncology,
vol. 18, no. 4, pp. 243–259, 2001.
[ 7 ]A .E .G r e i j e r ,M .C .d eJ o n g ,G .L .S c h e ﬀer, A. Shvarts,
P. J. van Diest, and E. van der Wall, “Hypoxia-induced
acidiﬁcation causes mitoxantrone resistance not mediated
by drug transporters in human breast cancer cells,” Cellular
Oncology, vol. 27, no. 1, pp. 43–49, 2005.
[8] L. Harrison and K. Blackwell, “Hypoxia and anemia: factors in
decreased sensitivitytoradiationtherapyandchemotherapy?”
Oncologist, vol. 9, supplement 5, pp. 31–40, 2004.
[9] G. L. Semenza, “Regulation of mammalian O2 homeostasis
by hypoxia-inducible factor 1,” Annual Review of Cell and
Developmental Biology, vol. 15, pp. 551–578, 1999.
[10] L. E. Huang, Z. Arany, D. M. Livingston, and H. F. Bunn,
“Activation of hypoxia-inducible transcription factor depends
primarily upon redox-sensitive stabilization of its α subunit,”
The Journal of Biological Chemistry, vol. 271, no. 50, pp.
32253–32259, 1996.
[11] R. D. Vaughan-Jones and K. W. Spitzer, “Role of bicarbonate
in the regulation of intracellular pH in the mammalian
ventricular myocyte,” Biochemistry and Cell Biology, vol. 80,
no. 5, pp. 579–596, 2002.
[ 1 2 ]K .S .C h o i ,M .K .B a e ,J .W .J e o n g ,H .E .M o o n ,a n dK .W .
Kim, “Hypoxia-induced angiogenesis during carcinogenesis,”
Journal of Biochemistry and Molecular Biology, vol. 36, no. 1,
pp. 120–127, 2003.
[13] T. Schmid, J. Zhou, and B. Br¨ une, “HIF-1 and p53: commu-
nication of transcription factors under hypoxia,” Journal of
Cellular and Molecular Medicine, vol. 8, no. 4, pp. 423–431,
2004.
[14] M. Koshiji and L. E. Huang, “Dynamic balancing of the dual
nature of HIF-1α for cell survival,” Cell Cycle,v o l .3 ,n o .7 ,p p .
853–854, 2004.
[15] K. A. Furge, Y. W. Zhang, and G. F. Vande Woude, “Met
receptor tyrosine kinase: enhanced signaling through adapter
proteins,” Oncogene, vol. 19, no. 49, pp. 5582–5589, 2000.
[16] S. Pennacchietti, P. Michieli, M. Galluzzo, M. Mazzone, S.
Giordano, and P. M. Comoglio, “Hypoxia promotes invasive
growth by transcriptional activation of the met protoonco-
gene,” Cancer Cell, vol. 3, no. 4, pp. 347–361, 2003.
[17] S. Hara, K. Nakashiro, S. K. Klosek, T. Ishikawa, S. Shintani,
and H. Hamakawa, “Hypoxia enhances c-Met/HGF receptor
expression and signaling by activating HIF-1α in human
salivary gland cancer cells,” Oral Oncology,v o l .4 2 ,n o .6 ,p p .
593–598, 2006.
[ 1 8 ]C .E c k e r i c h ,S .Z a p f ,R .F i l l b r a n d t ,S .L o g e s ,M .W e s t p h a l ,
and K. Lamszus, “Hypoxia can induce c-Met expression in
glioma cells and enhance SF/HGF-induced cell migration,”
International Journal of Cancer, vol. 121, no. 2, pp. 276–283,
2007.
[ 1 9 ]E .H .G o r t ,A .J .G r o o t ,E .v a nd e rW a l l ,P .J .v a nD i e s t ,a n d
M. A. Vooijs, “Hypoxic regulation of metastasis via hypoxia-
inducible factors,” Current Molecular Medicine, vol. 8, no. 1,
pp. 60–67, 2008.
[20] W. G. Kaelin Jr., “The von Hippel-Lindau tumor suppressor
protein and clear cell renal carcinoma,” Clinical Cancer
Research, vol. 13, no. 2, part 2, pp. 680s–682s, 2007.
[21] E. Laughner, P. Taghavi, K. Chiles, P. C. Mahon, and G. L.
Semenza,“HER2(neu)signalingincreasestherateofhypoxia-
inducible factor 1α (HIF-1α) synthesis: novel mechanism for
HIF-1-mediated vascular endothelial growth factor expres-
sion,”MolecularandCellularBiology, vol.21,no.12,pp.3995–
4004, 2001.
[22] W. Zundel, C. Schindler, D. Haas-Kogan, et al., “Loss of
PTEN facilitates HIF-1-mediated gene expression,” Genes and
Development, vol. 14, no. 4, pp. 391–396, 2000.
[ 2 3 ]E .H .G o r t ,A .J .G r o o t ,T .L .P .D e r k sv a nd eV e n ,e ta l . ,
“Hypoxia-inducible factor-1α expression requires PI 3-kinase
activity and correlates with Akt1 phosphorylation in invasive
breast carcinomas,” Oncogene, vol. 25, no. 45, pp. 6123–6127,
2006.Obstetrics and Gynecology International 7
[24] B. H. Jiang, G. Jiang, J. Z. Zheng, Z. Lu, T. Hunter, and P. K.
Vogt, “Phosphatidylinositol 3-kinase signaling controls levels
of hypoxia-inducible factor 1,” Cell Growth and Diﬀerentia-
tion, vol. 12, no. 7, pp. 363–369, 2001.
[ 2 5 ]R .R a v i ,B .M o o k e r j e e ,Z .M .B h u j w a l l a ,e ta l . ,“ R e g u l a t i o no f
tumor angiogenesis by p53-induced degradation of hypoxia-
inducible factor 1α,” Genes and Development, vol. 14, no. 1,
pp. 34–44, 2000.
[26] C. Treins, S. Giorgetti-Peraldi, J. Murdaca, G. L. Semenza,
and E. Van Obberghen, “Insulin stimulates hypoxia-inducible
factor 1 through a phosphatidylinositol 3-kinase/target of
rapamycin-dependent signaling pathway,” The Journal of Bio-
logical Chemistry, vol. 277, no. 31, pp. 27975–27981, 2002.
[27] C. C. Hudson, M. Liu, G. G. Chiang, et al., “Regulation
of hypoxia-inducible factor 1α expression and function by
the mammalian target of rapamycin,” Molecular and Cellular
Biology, vol. 22, no. 20, pp. 7004–7014, 2002.
[28] M. M. Vleugel, A. E. Greijer, E. van der Wall, and P. J. van
Diest, “Mutation analysis of the HIF-1α oxygen-dependent
degradationdomainininvasivebreastcancer,”CancerGenetics
and Cytogenetics, vol. 163, no. 2, pp. 168–172, 2005.
[29] M. M. Vleugel, R. Bos, H. Buerger, et al., “No ampliﬁcations
of hypoxia-inducible factor-1α gene in invasive breast cancer:
a tissue microarray study,” Cellular Oncology, vol. 26, no. 5-6,
pp. 347–351, 2004.
[30] X. S. Fu, E. Choi, G. J. Bubley, and S. P. Balk, “Identiﬁcation
of hypoxia-inducible factor-1α (HIF-1α) polymorphism as a
mutation in prostate cancer that prevents normoxia-induced
degradation,” Prostate, vol. 63, no. 3, pp. 215–221, 2005.
[ 3 1 ]N .H o r r e e ,A .J .G r o o t ,W .v a nH a t t e m ,A .P .H e i n t z ,M .
A. Vooijs, and P. J. van Diest, “HIF-1α gene mutations are
associated with higher microvessel density in endometrial
carcinomas,” Histopathology, vol. 52, no. 5, pp. 637–639, 2008.
[32] E. Konac, H. I. Onen, J. Metindir, E. Alp, A. A. Biri, and A.
Ekmekci, “An investigation of relationships between hypoxia-
inducible factor-1α gene polymorphisms and ovarian, cervical
and endometrial cancers,” Cancer Detection and Prevention,
vol. 31, no. 2, pp. 102–109, 2007.
[33] L. Speroﬀ,R .H .G l a s s ,a n dN .G .K a s e ,Clinical Gynecologic
Endocrinology and Infertility, Williams and Wilkins, Sydney,
Australia, 1994.
[34] J. Zhang and L. A. Salamonsen, “Expression of hypoxia-
inducible factors in human endometrium and suppression
of matrix metalloproteinases under hypoxic conditions do
not support a major role for hypoxia in regulating tissue
breakdown at menstruation,” Human Reproduction, vol. 17,
no. 2, pp. 265–274, 2002.
[35] N. Horr´ ee, P. J. van Diest, P. van der Groep, D. M. Sie-Go,
and A. P. Heintz, “Hypoxia and angiogenesis in endometrioid
endometrial carcinogenesis,” Cellular Oncology, vol. 29, no. 3,
pp. 219–227, 2007.
[36] I. H. Ozbudak, S. Karaveli, T. Simsek, G. Erdogan, and
E. Pestereli, “Neoangiogenesis and expression of hypoxia-
inducible factor 1α, vascular endothelial growth factor, and
glucose transporter-1 in endometrioid type endometrium
adenocarcinomas,” Gynecologic Oncology, vol. 108, pp. 603–
608, 2008.
[37] E. Sivridis, A. Giatromanolaki, K. C. Gatter, A. L. Harris, and
M. I. Koukourakis, “Association of hypoxia-inducible factors
1α and 2α with activated angiogenic pathways and prognosis
in patients with endometrial carcinoma,” Cancer, vol. 95, no.
5, pp. 1055–1063, 2002.
[ 3 8 ]G .A c s ,X .X u ,C .C h u ,P .A c s ,a n dA .V e r m a ,“ P r o g n o s t i cs i g -
niﬁcance of erythropoietin expression in human endometrial
carcinoma,” Cancer, vol. 100, no. 11, pp. 2376–2386, 2004.
[ 3 9 ]J .I .R i s i n g e r ,A .K .H a y e s ,A .B e r c h u c k ,a n dJ .C .B a r r e t t ,
“PTEN/MMAC1 mutations in endometrial cancers,” Cancer
Research, vol. 57, no. 21, pp. 4736–4738, 1997.
[40] D. Kong, A. Suzuki, T. T. Zou, et al., “PTEN1 is frequently
mutated in primary endometrial carcinomas,” Nature Genet-
ics, vol. 17, no. 2, pp. 143–144, 1997.
[41] D. E. Cohn, J. B. Basil, A. R. Venegoni, et al., “Absence
of PTEN repeat tract mutation in endometrial cancers with
microsatellite instability,” Gynecologic Oncology, vol. 79, no. 1,
pp. 101–106, 2000.
[42] M. Cully, H. You, A. J. Levine, and T. W. Mak, “Beyond PTEN
mutations: the PI3K pathway as an integrator of multiple
inputs during tumorigenesis,” Nature Reviews Cancer, vol. 6,
no. 3, pp. 184–192, 2006.
[43] J. M. A. Pijnenborg, M. Wijnakker, J. Hagelstein, B. Delvoux,
and P. G. Groothuis, “Hypoxia contributes to development
of recurrent endometrial carcinoma,” International Journal of
Gynecological Cancer, vol. 17, no. 4, pp. 897–904, 2007.
[44] V. Pansare, A. R. Munkarah, V. Schimp, et al., “Increased
expression of hypoxia-inducible factor 1α in type I and type
II endometrial carcinomas,” Modern Pathology, vol. 20, no. 1,
pp. 35–43, 2007.
[45] V. L. Schimp, R. Ali-Fehmi, L. A. Solomon, et al., “The racial
disparity in outcomes in endometrial cancer: could this be
explained on a molecular level?” Gynecologic Oncology, vol.
102, no. 3, pp. 440–446, 2006.
[46] H. Zhong, A. M. De Marzo, E. Laughner, et al., “Overex-
pression of hypoxia-inducible factor 1α in common human
cancers and their metastases,” Cancer Research, vol. 59, no. 22,
pp. 5830–5835, 1999.
[47] M. M. Vleugel, A. E. Greijer, A. Shvarts, et al., “Diﬀerential
prognostic impact of hypoxia induced and diﬀuse HIF-
1α expression in invasive breast cancer,” Journal of Clinical
Pathology, vol. 58, no. 2, pp. 172–177, 2005.
[ 4 8 ]D .S .M i l l e r ,J .A .B l e s s i n g ,S .S .L e n t z ,S .E .W a g g o n e r ,a n d
D. Mackey, “A phase II trial of topotecan in patients with
advanced, persistent, or recurrent endometrial carcinoma: a
gynecologic oncology group study,” Gynecologic Oncology, vol.
87, no. 3, pp. 247–251, 2002.
[49] T. A. Traina, P. Sabbatini, C. Aghajanian, and J. Dupont,
“Weekly topotecan for recurrent endometrial cancer: a case
series and review of the literature,” Gynecologic Oncology, vol.
95, no. 1, pp. 235–241, 2004.
[50] S. Wadler, D. E. Levy, S. T. Lincoln, G. S. Soori, J. C. Schink,
and G. Goldberg, “Topotecan is an active agent in the ﬁrst-line
treatment of metastatic or recurrent endometrial carcinoma:
Eastern Cooperative Oncology Group Study E3E93,” Journal
of Clinical Oncology, vol. 21, no. 11, pp. 2110–2114, 2003.
[51] A. M. Oza, L. Elit, D. Provencher, et al., “A phase II study
of temsirolimus (CCI-779) in patients with metastatic and/or
locally advanced recurrent endometrial cancer previously
treated with chemotherapy: NCIC CTG IND 160b,” Journal of
Clinical Oncology, vol. 26, no. 5, supplement, p. 5516, 2003.
[52] B. M. Slomovitz, K. H. Lu, T. Johnston, et al., “A pahse II study
of oral mammalian target of rapamycin (mTOR) inhibitor,
RAD001 (everolimus), in patients with recurrent endometrial
carcinoma (EC),” Journal of Clinical Oncology, vol. 26, no. 20,
supplement, p. 5502, 2008.8 Obstetrics and Gynecology International
[53] C. Aghajanian, M. W. Sill, K. Darcy, et al., “A phase II
evaluation of bevacizumab in the treatment of recurrent or
persistentendometrialcancer:aGynecologicOncologyGroup
(GOG) Study,” Journal of Clinical Oncology, vol. 27, no. 15,
supplement, p. 5531, 2009.
[54] G. L. Semenza, “Targeting HIF-1 for cancer therapy,” Nature
Reviews Cancer, vol. 3, no. 10, pp. 721–732, 2003.
[55] A. Giaccia, B. G. Siim, and R. S. Johnson, “HIF-1 as a target
for drug development,” Nature Reviews Drug Discovery, vol. 2,
no. 10, pp. 803–811, 2003.
[56] A. Rapisarda, R. H. Shoemaker, and G. Melillo, “Targeting
topoisomerase I to inhibit hypoxia inducible factor 1,” Cell
Cycle, vol. 3, no. 2, pp. 172–175, 2004.
[57] A. Rapisarda and G. Melillo, “UVC inhibits HIF-1alpha
protein translation by a DNA damage- and topoisomerase I-
independent pathway,” Oncogene, vol. 26, no. 48, pp. 6875–
6884, 2007.
[58] A. Rapisarda, B. Uranchimeg, D. A. Scudiero, et al., “Identiﬁ-
cationofsmallmoleculeinhibitorsofhypoxia-induciblefactor
1 transcriptional activation pathway,” Cancer Research, vol. 62,
no. 15, pp. 4316–4324, 2002.
[ 5 9 ]J .T .C h a m b e r s ,T .J .R u t h e r f o r d ,P .E .S c h w a r t z ,M .L .
Carcangiu, S. K. Chambers, and L. Baker, “A pilot study of
topotecan in the treatment of serous carcinoma of the uterus,”
InternationalJournalofGynecologicalCancer,v ol.13,no .2,pp .
216–222, 2003.
[60] H. Zhong, K. Chiles, D. Feldser, et al., “Modulation of
hypoxia-inducible factor 1α expression by the epider-
mal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/
FRAPpathwayinhumanprostatecancercells:implicationsfor
tumor angiogenesis and therapeutics,” Cancer Research, vol.
60, no. 6, pp. 1541–1545, 2000.
[61] M. S. Neshat, I. K. Mellinghoﬀ, C. Tran, et al., “Enhanced
sensitivity of PTEN-deﬁcient tumors to inhibition of
FRAP/mTOR,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 98, no. 18, pp.
10314–10319, 2001.
[62] H. S. Chon, W. Hu, and J. J. Kavanagh, “Targeted therapies in
gynecologic cancers,” Current Cancer Drug Targets, vol. 6, no.
4, pp. 333–363, 2006.
[63] A. Giatromanolaki, E. Sivridis, R. Brekken, et al., “he
angiogenic “vascular endothelial growth factor/ﬂk-1(KDR)
receptor” pathway in patients with endometrial carcinoma:
prognostic and therapeutic implications,” Cancer, vol. 92, pp.
2569–2577, 2001.
[64] N. Seki, J. Kodama, A. Hongo, Y. Miyagi, M. Yoshinouchi,
and T. Kudo, “Vascular endothelial growth factor and platelet-
derived endothelial cell growth factor expression are impli-
cated in the angiogenesis of endometrial cancer,” European
Journal of Cancer, vol. 36, no. 1, pp. 68–73, 2000.
[65] D. Rischin, L. Peters, R. Hicks, et al., “Phase I trial of concur-
rent tirapazamine, cisplatin, and radiotherapy in patients with
advanced head and neck cancer,” Journal of Clinical Oncology,
vol. 19, no. 2, pp. 535–542, 2001.
[66] M. C. A. Duyndam, M. P. A. van Berkel, J. C. Dorsman,
D. A. P. Rockx, H. M. Pinedo, and E. Boven, “Cisplatin
and doxorubicin repress Vascular Endothelial Growth Fac-
tor expression and diﬀerentially down-regulate Hypoxia-
inducible Factor I activity in human ovarian cancer cells,”
Biochemical Pharmacology, vol. 74, no. 2, pp. 191–201,
2007.
[67] G. F. Fleming, V. L. Brunetto, D. Cella, et al., “Phase III trial
of doxorubicin plus cisplatin with or without paclitaxel plus
ﬁlgrastim in advanced endometrial carcinoma: a Gynecologic
Oncology Group Study,” Journal of Clinical Oncology, vol. 22,
no. 11, pp. 2159–2166, 2004.
[68] S. Welsh, R. Williams, L. Kirkpatrick, G. Paine-Murrieta,
and G. Powis, “Antitumor activity and pharmacodynamic
properties of PX-478, an inhibitor of hypoxia-inducible
factor-1α,” Molecular Cancer Therapeutics, vol. 3, no. 3, pp.
233–244, 2004.
[69] J. L. O’Donnell, M. R. Joyce, A. M. Shannon, J. Harmey, J.
Geraghty, and D. Bouchier-Hayes, “Oncological implications
of hypoxia inducible factor-1α (HIF-1α) expression,” Cancer
Treatment Reviews, vol. 32, no. 6, pp. 407–416, 2006.
[70] E. Minet, D. Mottet, G. Michel, et al., “Hypoxia-induced
activation of HIF-1: role of HIF-1α-Hsp90 interaction,” FEBS
Letters, vol. 460, no. 2, pp. 251–256, 1999.